Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.

Abstract

Hypersensitivity reactions are reported in approximately 5% of adults receiving abacavir, but there are few published data in children. Among 1150 African children receiving antiretroviral therapy in a randomized trial, suspected hypersensitivity reactions to abacavir were rare (0.3%; 95% CI, 0.01-0.9). Patients were managed successfully through the provision of clear guidelines and education of clinical staff, children, and their caregivers.

• Authors: Patricia Nahirya-Ntege, Victor Musiime, Bethany Naidoo, Sabrina Bakeera-Kitaka, Kusum Nathoo, Paula Munderi, Peter Mugyenyi, Adeodata Kekitiinwa, Mutsa F Bwakura-Dangarembizi, Jane Crawley, ARROW Trial Team
• Journal: The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 30 Issue 6 Pg. 535-7 (Jun 2011) ISSN: 1532-0987 [Electronic] United States
• PMID: 21164384 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• Dideoxynucleosides
• abacavir

Topics

• Adolescent
• Africa
• Anti-HIV Agents (administration & dosage, adverse effects)
• Antiretroviral Therapy, Highly Active (adverse effects)
• Child
• Child, Preschool
• Dideoxynucleosides (administration & dosage, adverse effects)
• Female
• HIV Infections (drug therapy)
• Humans
• Hypersensitivity (epidemiology)
• Incidence
• Infant
• Male